These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
561 related articles for article (PubMed ID: 34519567)
61. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Ross S Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082 [TBL] [Abstract][Full Text] [Related]
62. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; O'Donnell M; Carter O; Liknaitzky P; Williams M; Siskind D; Penington D; Berk M; Castle D Aust N Z J Psychiatry; 2021 Dec; 55(12):1127-1133. PubMed ID: 33745287 [TBL] [Abstract][Full Text] [Related]
63. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. Barnett BS; Parker SE; Weleff J Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734 [TBL] [Abstract][Full Text] [Related]
65. Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia. Strauss N Med J Aust; 2017 Jun; 206(11):468-469. PubMed ID: 28918722 [No Abstract] [Full Text] [Related]
66. Role of Psychedelics in Treatment-Resistant Depression. Kamal S; Jha MK; Radhakrishnan R Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346 [TBL] [Abstract][Full Text] [Related]
68. Psilocybin-assisted therapy for depression: How do we advance the field? Meikle SE; Liknaitzky P; Rossell SL; Ross M; Strauss N; Thomas N; Murray G; Williams M; Castle DJ Aust N Z J Psychiatry; 2020 Mar; 54(3):225-231. PubMed ID: 31752499 [TBL] [Abstract][Full Text] [Related]
69. Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. Henningfield JE; Ashworth J; Heal DJ; Smith SL J Psychopharmacol; 2023 Jan; 37(1):33-44. PubMed ID: 36588452 [TBL] [Abstract][Full Text] [Related]
75. Towards an understanding of psychedelic-induced neuroplasticity. Calder AE; Hasler G Neuropsychopharmacology; 2023 Jan; 48(1):104-112. PubMed ID: 36123427 [TBL] [Abstract][Full Text] [Related]
76. Pharmacologic Similarities and Differences Among Hallucinogens. Waters K J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S100-S113. PubMed ID: 34396556 [TBL] [Abstract][Full Text] [Related]
77. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974 [TBL] [Abstract][Full Text] [Related]
78. Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. Rocha JM; Osório FL; Crippa JAS; Bouso JC; Rossi GN; Hallak JEC; Dos Santos RG Ther Adv Psychopharmacol; 2019; 9():2045125319845774. PubMed ID: 31065350 [TBL] [Abstract][Full Text] [Related]
79. Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects. Abramson HA; Rolo A J Asthma Res; 1965 Sep; 3(1):81-96. PubMed ID: 5318626 [No Abstract] [Full Text] [Related]